NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02908672,A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma,https://clinicaltrials.gov/study/NCT02908672,,COMPLETED,"This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.",YES,Melanoma,DRUG: Atezolizumab|DRUG: Atezolizumab Placebo|DRUG: Cobimetinib|DRUG: Vemurafenib|DRUG: Vemurafenib Placebo,"Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first, Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)","Progression-Free Survival (PFS), as Determined by Independent Review Committee Using RECIST v1.1, PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by an IRC according to RECIST v1.1, or death from any cause, whichever occurs first, Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Percentage of Participants With Objective Response, as Determined by Investigator Using RECIST v1.1, Objective response is defined as a CR or PR on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1, Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Duration of Response, as Determined by Investigator Using RECIST v1.1, DOR, defined as the time from the first occurrence of a documented objective response to disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first, Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Overall Survival, OS is defined as the time from randomization to death from any cause, Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Percentage of Participants Who Have Survived at 2 Years, 2-year landmark survival, defined as survival at 2 years, 2 years|Time to Deterioration in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Scale Score, Time to deterioration in global health status/healthrelated quality of life (GHS/HRQoL), defined as the time from randomization to first observed ≥ 10-point decrease in EORTC QLQ-C30 linearly transformed GHS/HRQoL scale score that is sustained for two consecutive assessments or followed by death while the participant is on treatment.

The score range for each EORTC QLQ-C30 scale is from 0 to 100, with higher scores indicating better functioning and better GHS/HRQoL., Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Time to Deterioration in Physical Functioning Using EORTC QLQ-C30 Physical Functioning Scale Score, Time to deterioration in physical functioning, defined as the time from randomization to first observed ≥ 10-point decrease in EORTC QLQ-C30 linearly transformed physical functioning scale score that is sustained for two consecutive assessments or followed by death while the participant is on treatment.

The score range for each EORTC QLQ-C30 scale is from 0 to 100, with higher scores indicating better functioning and better GHS/HRQoL., Baseline up to disease progression or death due to any cause, whichever occurs first (up to approximately 33 months)|Percentage of Participants With Adverse Events and Serious Adverse Events, Baseline up to 6 months after the last dose of study treatment (approximately 33 months)|Serum Concentration of Atezolizumab, Pre-infusion Day 1 of Cycles 1-4; 30 minutes post-infusion Day 1 of Cycles 1 and 4; at Atezolizumab discontinuation (up to approximately 33 months)(1 Cycle = 28 days)|Plasma Concentration of Cobimetinib Dose: 20/40 mg, Pre-dose (0 hour) and 3 to 6 hours post dose on Day 15 of Cy 1 and 4 (1 Cy = 28 days)|Plasma Concentration of Cobimetinib Dose: 60 mg, Pre-dose (0 hour) and 3 to 6 hours post dose on Day 15 of Cy 1 and 4 (1 Cy = 28 days)|Plasma Concentration of Vemurafenib, Pre-dose (0 hour) and 3 to 6 hours post dose on Day 15 of Cy 1 and 4 (1 Cy = 28 days)|Percentage of Participants Positive for Anti-Drug Antibodies (ADA) to Atezolizumab, Presence of ADAs against atezolizumab during the study relative to the presence of ADAs at baseline, Pre-infusion Day 1 of Cycles 1-4; at Atezolizumab discontinuation (up to approximately 90 months)(1 Cycle=28 days) (approximately up to 33 months)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,514,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",CO39262|2016-002482-54,2017-01-13,2019-10-11,2024-07-01,2016-09-21,2020-11-19,2024-10-01,"University of Alabama at Birmingham, Birmingham, Alabama, 35294-3300, United States|Arizona Oncology Associates, PC - HAL, Tempe, Arizona, 85284, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|UC Irvine Medical Center, Orange, California, 92868, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, 32824, United States|Oncology Specialists, S.C., Park Ridge, Illinois, 60068, United States|St. Luke's University Health network, Bethlehem, Pennsylvania, 18015, United States|Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Peter Maccallum Cancer Centre, Melbourne, Victoria, 3000, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6150, Australia|Medical University of Graz, Department of Dermatology, Graz, 8030, Austria|LKH Innsbruck; Universitätsklinik für Dermatologie, Innsbruck, 6020, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, 1090, Austria|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|CHU Sart-Tilman, Liège, 4000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Clinicas Oncologicas Integradas - COI, Rio De Janeiro, RJ, 22290-160, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-903, Brazil|Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN, Florianopolis, SC, 88020-210, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, 01246-000, Brazil|Beneficencia Portuguesa de Sao Paulo, São Paulo, SP, 01321-00, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, T2N 4N2, Canada|Juravinski Cancer Clinic; Department of Oncology, Hamilton, Ontario, L8V 5C2, Canada|LHSC - Victoria Hospital; London Regional Cancer Program, London, Ontario, N6A 4L6, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, L1G 2B9, Canada|The Ottawa Hospital Cancer Centre; Oncology, Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Hospital, Toronto, Ontario, M4X 1K9, Canada|CHU de Quebec - Hopital de l'Enfant-Jesus; Unite de Recherche en Hematologie et Oncologie, Quebec, G1J 1Z4, Canada|Groupe Hospitalier Saint André - Hôpital Saint André, Bordeaux, 33075, France|Hopital du Bocage; Dermatologie, Dijon, 21079, France|Centre Hospitalier Universitaire de Grenoble - Albert Michallon, La Tronche, 38700, France|Hopital Claude Huriez - CHU Lille, Lille, 59037, France|Hopital Saint Eloi; CHU de Montpellier; Svc de Dermatologie, Montpellier, 34295, France|CHU de Nantes; Cancéro-dermatologie, Nantes, 44093, France|Hopital Robert Debre; DERMATOLOGIE, Reims, 51092, France|Centre Eugene Marquis; Service d'oncologie, Rennes, 35042, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, 76031, France|Institut Gustave Roussy; Dermatologie, Villejuif, 94805, France|Charite - Universitätsmedizin Berlin, Berlin, 12203, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, 21614, Germany|HELIOS Klinikum Erfurt; Klinik für Dermatologie & Allergologie, Erfurt, 99089, Germany|Universitätsklinikum Erlangen; Hautklinik, Erlangen, 91054, Germany|Universitatsklinikum Essen; Klinik für Dermatologie, Essen, 45147, Germany|Universitätsmedizin Göttingen; Klinik für Gastroenterologie, gastrointestinale, Göttingen, 37075, Germany|Medizinische Hochschule Hannover; Klinik für Dermatologie, Allergologie und Venerologie, Hannover, 30625, Germany|Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg, 69120, Germany|UKSH Kiel; Klinik für Dermatologie, Venerologie und Allergologie, Kiel, 24105, Germany|Klinikum d.Universität zu Köln Klinik u.Poliklinik f.Dermatologie, Köln, 50937, Germany|Universitätsklinikum Leipzig; Klinik für Dermatologie, Venerologie und Allergologie, Leipzig, 04103, Germany|UKSH Universitatsklinikum Schleswig-Holstein; Studienzentrum Dermatologie 10d, Lübeck, 23538, Germany|Universitatsklinikum Mainz; Klinik und Poliklinik fur Dermatologie, Mainz, 55131, Germany|Klinikum der Ludwigs-Maximilians-Universität München; Dermatologie, München, 80337, Germany|Fachklinik Hornheide; Dermatologie, Münster, 48157, Germany|Harzklinikum Dorothea Christiane Erxleben GmbH, Standort Quedlinburg; Hautkrebszentrum Harz, Quedlinburg, 06484, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, 93053, Germany|Zentrum für Dermatoonkologie, Universitäts-Hautklinik Tübingen, Tübingen, 72076, Germany|Universitätsklinikum Würzburg; Med. Klinik 1, Pneumologie, Würzburg, 97080, Germany|Laiko General Hospital Athen, Athens, 115 27, Greece|Metropolitan Hospital; Dept. of Oncology, Pireaus, 185 47, Greece|Orszagos Onkologiai Intezet; Borgyogyaszati Osztaly, Budapest, 1122, Hungary|University of Szeged Szent-Györgyi Albert Clinical Center; Department of Dermatology and Allergology, Szeged, 6720, Hungary|Rambam Health Care Campus; Oncology, Haifa, 3109601, Israel|Sharett Institute - Hadassah Hebrew University Medical Center, Jerusalem, 9112001, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, 4941492, Israel|Ella Institute - Sheba Medical Center, Ramat-Gan, 5265601, Israel|IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica B, Napoli, Campania, 80131, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, 47014, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, 00144, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, 16132, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, 20133, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, 20141, Italy|Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico, Candiolo, Piemonte, 10060, Italy|Istituto Tumori ?Giovanni Paolo II?, Oncologia, Bari, Puglia, 70124, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, 53100, Italy|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Erasmus Mc - Daniel Den Hoed Kliniek; Interne Oncologie, Rotterdam, 3015AA, Netherlands|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, 1023, New Zealand|Wellington Hospital; Wellington Blood and Cancer Centre, Newtown, 6021, New Zealand|Mid Central DHB, Palmerston North, 4442, New Zealand|Tauranga Hospital, Clinical Trials Unit; BOP Clinical School, Tauranga, 3112, New Zealand|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk, 80-214, Poland|Narodowy Inst.Onkol.im.Sk?odowskiej-Curie Pa?stw.Inst.Badawczy Kraków; Klinika Onkologii Klinicznej, Kraków, 31-115, Poland|COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej, Lublin, 20-090, Poland|Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, 60-780, Poland|Narodowy Instytut Onkologii im. Marii Sk?odowskiej-Curie - Pa?stwowy Instytut Badawczy, Warszawa, 02-781, Poland|Dolno?l?skie Centrum Onkologii, Pulmonologii i Hematologii, Wroc?aw, 53-413, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Moskovskaja Oblast, 115478, Russian Federation|FBI ""Scientific Research Institute of Oncology n. a. N. N. Petrov"", Saint-Petersburg, Sankt Petersburg, Russian Federation|St. Petersburg Oncology Hospital, Sankt-peterburg, Sankt Petersburg, 198255, Russian Federation|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, 31008, Spain|Hospital Universitari Vall d'Hebron; Oncology, Barcelona, 08035, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, 08036, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, 28034, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Universitario Virgen de la Macarena;, Sevilla, 41071, Spain|Fundacion Instituto Valenciano de Oncologia (IVO), Valencia, 46009, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, 46014, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Bristol Haematology and Oncology centre, Bristol, BS2 8ED, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Ipswich Hospital; Oncology Pharmacy, Ipswich, IP4 5PD, United Kingdom|St James Uni Hospital; Icrf Cancer Medicine Research Unit, Leeds, LS9 7TF, United Kingdom|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, SE1 9RT, United Kingdom|Freeman Hospital; Northern Centre For Cancer Care, New Castle Upon Tyne, NE7 7DN, United Kingdom|Singleton Hospital; Pharmacy Department, Swansea, SA2 8QA, United Kingdom|Royal Cornwall Hospital, Truro, TR1 3LQ, United Kingdom","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/72/NCT02908672/Prot_SAP_000.pdf"
